October 10, 2013 CDISC SHARE and CFAST Integrally Linked: A Major Topic at the 2013 CDISC International Interchange
U.S. Food and Drug Administration and European Medicines Agency Reach Landmark Decisions on Critical Path Institute’s Clinical Trial Simulation Tool for Alzheimer’s Disease
CFAST Announces Parkinson’s Disease Drug Development Milestone: Release and Availability of a PD Therapeutic Area Data Standard
The National Multiple Sclerosis Society and Critical Path Institute Create the Multiple Sclerosis Outcome Assessments Consortium
CDISC, C-Path and FDA Collaborate to Develop Data Standards to Streamline Path to New Therapies The Clinical Data Interchange Standards Consortium (CDISC) and the Critical Path Institute (C-Path) announce the signing of a part
European Medicines Agency Deems Imaging Biomarker a Qualified Measure to Select Patients with Early Stages of Cognitive Impairment for Alzheimer’s Disease Clinical Trials Based on a request for regulatory review by Critical Path Institute’s (C-Path) Coalition Against Major Diseases (CAMD), the
